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Abstract
In this report, we describe the construction and characterization of the first full-length infectious molecular clone from the Cameroonian
HIV-1 group O primary isolate MVP8913. Virus obtained after transfection of the proviral clone pCMO2.3 replicated to levels comparable to
its parental isolate in the human T-cell line PM-1, although replication was reduced by fivefold in peripheral blood mononuclear cells
(PBMC) and was barely detectable in primary monocyte-derived macrophages (MDM). Phylogenetic analysis of the complete proviral
sequence revealed a closer relationship to ANT70 than to MVP5180, the two prototypic group O primary isolates. All reading frames for
structural and accessory genes were open except for vpr that contained an in-frame stop codon. In the nef gene, a mutation disrupting the
functionally important myristoylation signal was observed. Repairing the defect in nef enhanced replication in PBMC and MDM, although
repairing the vpr defect only affected replication in MDM, consistent with the known phenotypes of vpr and nef mutants in HIV-1 group M
viruses. Repairing both vpr and nef showed an additive effect, but the resulting virus was still impaired compared to the parental isolate. This
defect was overcome when the gag-pol coding region was exchanged for that from another O-type isolate giving rise to the proviral clone
pCMO2.5. Virus obtained from pCMO2.5 replicated with similar kinetics as the parental O-type isolate in both PBMC and MDM, making
this proviral clone a valuable tool for further studies on functional characteristics of HIV-1 group O viruses.
D 2004 Elsevier Inc. All rights reserved.
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Cameroon and its neighbors show the largest variety of
human immunodeficiency viruses with HIV-1 groups M, N,
and O reported from this region. Group M (main) viruses,
which are the most dominant HIV strains globally, are
composed of subtypes A–D, F–H, J–K, and various
circulating recombinant forms (CRF), although group N0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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(H.-G. Kr7usslich).viruses are rare with only two isolates reported (Robertson
et al., 2000). Group O (outlier) viruses have their epicenter
in Cameroon with a prevalence of 3–7% of all HIV
infections in this country (Gqrtler et al., 1994; Mauclere et
al., 1997; Zekeng et al., 1994). Group O infections have also
been reported in other parts of Africa, Europe, and the
United States (Hampl et al., 1995; Jonassen et al., 1997;
Loussert-Ajaka et al., 1995; Peeters et al., 1997; Rayfield et
al., 1996). Recently, two independent studies identified O/M
recombinant viruses from Cameroonian patients (Peeters et
al., 1999; Takehisa et al., 1999).
Group O viruses share only approximately 65% and 56%
nucleotide sequence homology with other groups of HIV-1 and
HIV-2, respectively (Gqrtler et al., 1994). Despite this genetic04) 329–339
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immunodeficiency viruses exhibits no major functional differ-
ences compared to the more thoroughly studied main group of
HIV-1. Several experimental results indicated, however, that O-
type viruses show some peculiarities. An interesting example is
the differential dependence ofHIVgroups on the cellular protein
cyclophilin A (CypA). HIV-1 M viruses incorporate CypA and
need it for efficient replication, although HIV-2 neither
incorporates nor requires CypA (Braaten et al., 1996; Franke
et al., 1994). Group O viruses, on the other hand, always
package CypA into the virion, but only some O isolates require
it, although others replicate independently of CypA (Braaten et
al., 1996; Wiegers and Kr7usslich, 2002). This functional
divergence suggests that analysis of HIV-1 groupO viruses may
aid in elucidating the role of CypA in HIV replication.
Furthermore, in vitro data indicated that group O viruses are
resistant to TIBO non-nucleoside analogues and less susceptible
to protease inhibitors than group M isolates (Descamps et al.,
1998; Quinon˜es-Mateu et al., 1998).
Most phylogenetic studies on HIV-1 group O have been
limited to partial gene sequences, and until very recently
(Yamaguchi et al., 2003), only four full-length sequences of
group O viruses were available in the HIV database. Detailed
characterization of functional differences between different
virus isolates requires the availability of infectious molecular
clones, which are difficult to generate due to the high rate of
defective viral genomes occurring during the course of HIV
infection (Li et al., 1991). Accordingly, all currently available
HIV-1 infectious molecular clones are derived from group M
isolates, mostly from subtypes B and D. There are about a
dozen infectious molecular clones representing other HIV-1
group M subtypes (subtypes A and C) and CRF (CFR01.AE
and CRF02.AG) (Gao et al., 1998; Ndung’u et al., 2001;
Salminen et al., 2000; Takahoko et al., 2001; Tebit et al.,
2003), but no infectious clone of an O-group isolate has been
reported. Here, we describe the construction and character-
ization of such an HIV-1 group O full-length infectious
molecular clone from the Cameroonian primaryHIV-1 isolate
MVP8913. Virus derived from transfection of this proviral
clone replicated efficiently in a T-cell line, but was impaired
in peripheral blood mononuclear cells (PBMC) and primary
monocyte-derived macrophages (MDM). Repairing defects
identified in the vpr and nef genes of the molecular clone
partially restored replication in PBMC and MDM, although
exchanging the gag-pol region for that from another O-group
isolate yielded virus replicating as efficiently as its parental
isolate in T-cell lines and primary cells.Fig. 1. (A) Strategy to generate full-length infectious molecular clones. The
genome was amplified by PCR in two halves. The 5V fragments were
cloned, and PCR products of the 3V fragments were directly introduced
using a newly generated MluI site. (B) Western blot analysis of PM-1 cells
infected with transfection-derived virus from molecular clones. Blots were
stained with a mixture of polyclonal antisera against MA, CA, RT, and IN
of HIV-1 group M (lanes 1–6) or pooled sera from three HIV-1 group O
infected patients (lanes 7–12). Lanes 1, 7: CMO2.1; lanes 2, 8: CMO2.2;
lanes 3, 9: CMO2.3 (2nd passage); lanes 4, 10: CMO2.3 (1st passage);
lanes 5, 11: NL4-3; lanes 6, 12: mock.Results
Construction of full-length molecular clones of HIV-1
group O
The genomic sequence of the HIV-1 group O isolate
MVP8913 was amplified by long range PCR (Barnes, 1994)from proviral DNA. Because of sequence redundancies in
the LTRs, the 5V- and 3V-halves were amplified separately
and combined using unique restriction sites as described
(Herchenrfder et al., 1995; Tebit et al., 2003). The isolate
MVP8913 was chosen because it uses CCR5, the coreceptor
most commonly required for entry by group O viruses
(Dittmar et al., 1999), and it is one of those group O isolates
that require CypA for efficient replication (Wiegers and
Kr7usslich, 2002). Four independent 5V PCR products
spanning the region from the 5V LTR to the vpr gene (5.7
kb) and carrying a novel unique MluI site in vpr were
amplified and cloned into pBluescript. PCR products
spanning the 3V region of the genome from vpr to the 3V
LTR (4.2 kb) and carrying an MluI site in the same position
in vpr as above were directly cloned into these four plasmids
(Fig. 1A). The artificial MluI site does not alter the coding
sequence of vpr or any known cis-acting element.
Initially, 16 full-length clones were obtained representing
four 5V PCR fragments and sixteen 3V PCR fragments (Table
1). Following transfection of 293T cells, production of HIV
CA antigen was observed for each of the clones. However,
all transfection-derived supernatants scored negative when
screened for infectivity on either PM-1 cells or PBMC
(Table 1). Cotransfection of clones #12 and #14 led to
production of infectious virus, indicating that these two
Table 1
Properties of the 25 full-length HIV-1 group O molecular clones derived by
long-range PCR
Plasmid Transfections (CA antigen)a Infections (CA antigen)b
293T HeLaP4 PM-1 PBMCs
1–16 ++ ++  
12 + 14c ++ ++ ++ +
18–22 ++ ++  
23 (CMO2.1) ++ ++ + F
24 (CMO2.2) ++ ++ + F
25 (CMO2.3) ++ ++ ++ +
++ = CA antigen production N100 ng/ml.
+ = CA antigen production b100 ng/ml.
F = very slow replication indicated by low production of CA antigen b10
ng/ml.
 = no production of CA antigen.
a All clones produced CA antigen upon transfection of both 293T cells and
HeLa P4 cells.
b Only three clones could infect PM-1 or PBMC to varying levels (see
results).
c Clones 12 and 14 produced infectious virus upon cotransfection.
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Swapping the 3V fragments of these two clones, however, did
not lead to production of infectious virus. Western blot
analysis of transfected cells revealed strong expression of
Gag and Pol proteins for clone #12, but weak expression for
clone #14 (data not shown), suggesting a defect in the 5V
fragment of clone #14. Therefore, additional 3V PCR
fragments were amplified and cloned into plasmid #12,
giving rise to eight new full-length clones (clones #18 to 25;
Table 1). Testing for infectivity using transfection-derived
virus demonstrated that the three proviral clones termed
CMO2.1, CMO2.2, and CMO2.3 yielded infectious virus
(Table 1). This was confirmed by Western blot analysis of
infected PM-1 cells using either pooled antisera against MA,
CA, RT, and IN of HIV-1 group M (Fig. 1B, lanes 1–6) or
pooled sera from patients infected with HIV-1 group O (Fig.
1B, lanes 7–12). O-group proteins were poorly reactive withFig. 2. Replication kinetics of viruses derived from molecular clones in (A) PM-1
500 or 1500 TCID50, respectively, of CMO2.3 (closed circles), NL4-3 (open ci
monitored by sampling medium for CA antigen every other day for 2 and 3 weethe M-group-specific sera except for CA, and the M-group
virus NL4-3 was weakly reactive with sera from HIV-1-O-
infected patients. There was a consistent lack of cross-
reactivity for the MA proteins, further emphasizing the
limited serologic cross-reactivity between group M and O
viruses.
Characterization of viruses derived from infectious
molecular clones
To characterize the viruses derived from plasmids
pCMO2.1, pCMO2.2, and pCMO2.3, we analyzed the
replication kinetics of these viruses, their parental isolate
MVP8913, and the M group virus NL4-3 in PM-1 cells and
PBMC. Replication was monitored by measuring CA
antigen in culture supernatants. In PM-1 cells, efficient
replication at levels similar to the parental isolate was
observed for CMO2.3 (Fig. 2A), although CMO2.1 and
CMO2.2 viruses replicated about 10-fold less efficiently
than CMO2.3 and MVP8913 (Table 1). We therefore
selected CMO2.3 for further analysis and evaluated its
replication characteristics in PHA/IL-2-stimulated PBMC
for 3 weeks. We consistently observed a fivefold reduced
replication for CMO2.3 compared to the parental MVP8913
isolate (Fig. 2B), indicating a defect in the CMO2.3 genome
that had not been apparent in the T-cell line. Both CMO2.3
and its parental isolate MVP8913 showed an NSI phenotype
on MT-2 cells and used CCR5 as a coreceptor on GHOST
cells (data not shown).
Molecular characterization and phylogenetic analysis
The complete proviral sequence of CMO2.3, consisting
of 9868 nucleotides, was determined. Phylogenetic analysis
showed that CMO2.3 clusters with HIV-1 group O isolates
and is more closely related to the prototype ANT70 than to
the other prototype MVP5180 (Fig. 3). This was further
confirmed when the respective nucleotide sequence homolo-
gies of individual genes were compared. CMO2.3 sharedcells and (B) PBMC. PM-1 cells and stimulated PBMC were infected with
rcles), or the primary isolate MVP8913 (open squares). Viral growth was
ks, respectively. Experiments were done twice in quadruplicate.
Fig. 3. Phylogenetic relationship of the full-length genomic sequences of representatives from HIV-1 groups M and O. The new CMO2.3 sequence is boxed.
The first letter identifying each isolate represents the subtypes (or group for HIV-1-O). Groups M and O are identified on the right. The tree was constructed
using the neighbor joining method and rooted with SIVcpzGab as out-group. The reliability of the branching order was confirmed by bootstrapping (100
replicates) shown at the nodes. CMO2.3 clusters with group O strains particularly with the prototypic ANT70 strain and two Senegalese isolates (99SE-
MP1299 and SE-MP1300).
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respectively, with ANT70 in gag, pol, env, and nef,
compared with 88%, 90%, 80%, and 84%, respectively,
with MVP5180. Considering the fact that intergroup
recombinants between HIV-1 M and -O have been reported,
the entire genome of CMO2.3 was analyzed using boot-
scanning and similarity plot methods (data not shown).
These analyses confirmed that pCMO2.3 contains a
complete and nonrecombinant O-type sequence. Thus,
pCMO2.3 represents the first full-length infectious mole-
cular clone of HIV-1 group O described.
Analysis of the CMO2.3 sequence revealed that reading
frames for the structural (gag, pol, env) and accessory
genes (vif, vpu, rev, tat, nef) were open, except for vpr
that contained an in-frame stop codon in position 18 of the
coding sequence. Furthermore, the second exon of tat
contained a premature termination site 17 codons upstream
of the regular stop codon, as has been found in other HIV-
1-O isolates (Kane et al., 2001). A functionally important
glycine to glutamic acid exchange was observed in the
second codon of the nef gene of CMO2.3, which disrupts
the signal for N-terminal myristoylation of Nef. Examining
the LTR sequences of CMO2.3 indicated that binding sites
for the critical transcription factors NFnB and SP1 as wellas the TATA motif were present. The binding site for the
Lys tRNA primer was essentially the same as in other
group O viruses. In the RT sequence of the pol gene, the
codon changes A98G, V179E, and Y181C compared to
HIV-1 M were observed, which have been associated with
the natural resistance to non-nucleoside reverse transcrip-
tase inhibitors (Quinon˜es-Mateu et al., 1997). The V3
sequences in the env genes of CMO2.3 and of the
prototypic isolate MVP5180 were identical, both consisting
of 39 codons, although the V3 region of the other
prototype ANT70 consisted of 36 codons. The hexameric
tip of the V3 loop of CMO2.3 showed a GPMAWY motif
that is also found in ANT70. The gp120 coding sequence
of CMO2.3 contained 32 glycosylation sites, three more
than in ANT70.
Repair of nef and vpr defects in pCMO2.3
The proviral clone pCMO2.3 contains mutations in vpr
and nef that may be important for its reduced replication
capacity compared to the parental isolate. The mutation in
the second codon of nef disrupts the signal for myristoy-
lation of Nef. This mutation is expected to abolish Nef
function because N-terminal myristoylation is required for
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for nearly all its biological activities (Geyer et al., 2001).
Examination of other HIV-1 group O sequences and direct
sequencing of the respective region of the parental isolate
MVP8913 revealed that this defect was specific for
pCMO2.3, since the other nef genes contained a glycine
codon in position 2. We therefore repaired the myristoyla-
tion signal in pCMO2.3 by PCR-based mutagenesis to give
the proviral plasmid pCMO2.31. Subsequently, the sub-
cellular localization of the different Nef proteins was
determined in infected cells. PM-1 cells were infected with
the parental isolate MVP8913, CMO2.3, and CMO2.31 and
analyzed 5 days post-infection. Cells were stained for CA
and Nef antigens (Fig. 4, left and right panels, respectively).
In cells infected with MVP8913, Nef was predominantly
observed in patched structures at the plasma membrane with
a minor population distributed homogeneously in the
cytoplasm (Fig. 4). This localization is presumed to reflect
efficient membrane targeting of myristoylated Nef. In
contrast, virtually, no Nef was detected in plasma membrane
patches in cells infected with CMO2.3, where Nef was
predominantly detected in the cytoplasm (Fig. 4). This
subcellular distribution is comparable to that described for
non-myristoylated Nef in T cells (Krautkr7mer et al., 2004).
Importantly, repairing the myristoylation site in CMO2.31
completely restored plasma membrane localization of Nef
(Fig. 4).Fig. 4. Fluorescence micrographs of PM-1 cells infected with viruses
bearing an intact myristoylation signal (MVP8913 and CMO2.31) and
CMO2.3, lacking the myristoylation acceptor glycine at position 2. Cells
were stained with antibodies against CA (left) and Nef (right) and detected
by fluorescent secondary antibodies. Each CA and Nef pair is shown in a
box. Arrows indicate the membrane or cytoplasmic localization of Nef,
respectively.The second obvious defect in pCMO2.3 was an in frame
stop codon in the vpr gene. This stop codon was also
detected upon direct sequencing of vpr from the parental
isolate MVP8913. Sequencing of individual clones indi-
cated that the primary isolate MVP8913 was composed of a
mixture of approximately 20% vpr+ and 80% vpr viruses.
To determine whether the vpr defect was responsible for the
replication difference in PBMC, the in-frame stop codon in
vpr was repaired by exchanging it for the vpr+ sequence of
the primary isolate. The resulting clone was termed
pCMO2.4 and cells infected with virus derived from this
clone were shown to produce Vpr (data not shown). In order
to obtain a full-length O-type clone with nondefective
accessory genes, the repair mutations in nef and vpr were
combined to give pCMO2.41.
Viral stocks were obtained by transfection of pCMO2.3,
pCMO2.31, pCMO2.4, and pCMO2.41, and replication
kinetics were determined on PM-1 cells and PBMC and
compared with the parental virus MVP8913. As expected,
there was no difference in the replication properties of the
O-type variants in PM-1 cells, where CMO2.3 replicated
with similar properties as its parental isolate (Fig. 5A). Upon
infection of PHA/IL-2 prestimulated PBMC, on the other
hand, virus replication was reduced fivefold when CMO2.3
was compared with MVP8913 (Fig. 5B). Repair of the vpr
stop codon did not alter the replication properties on blasted
PBMC and CMO2.4 replicated with comparable kinetics as
CMO2.3 (Fig. 5B). Repair of the nef defect, on the other
hand, led to a partial rescue with CMO2.31 replicating at
intermediate levels (Fig. 5B). There was no additive effect
when the defect in vpr was repaired in addition, and
CMO2.41 showed similar replication properties as
CMO2.31 (Fig. 5B).
Exchange of the gag-pol region leads to a fully functional
proviral clone
Because the replication of CMO2.41 was still impaired
in PBMC compared to its parental isolate, we decided to
replace the entire 5V fragment of pCMO2.41 (5V LTR to vpr)
with that from another O-type isolate. The primary isolate
MVP2171 (Dittmar et al., 1999) was chosen because it
replicates very efficiently in T-cell lines (unpublished data).
The 5V fragment was amplified by long PCR and inserted
into pCMO2.41 to give pCMO 2.5. Virus was produced by
transfection of 293T cells and replication kinetics were
analyzed in PBMC. CMO2.5 replicated at levels compara-
ble to the MVP8913 primary isolate and completely
rescued the remaining defect of CMO2.41 (Fig. 6A). This
result indicated that the residual replication defect in
CMO2.41 may have been due to variation in the gag-pol
sequence. Multiple sequence differences throughout the
exchanged region were observed when the gag-pol and vpr
sequences of CMO2.5 and CMO2.41 were compared, but
there were no obvious differences indicative of a specific
defect.
Fig. 5. Replication kinetics of Nef/Vpr(CMO2.3), Nef+/Vpr(CMO2.31), Nef/Vpr+(CMO2.4), and Nef+/Vpr+(CMO2.41) viruses in (A) PM-1 cells and
(B) PBMC. Infection of PM-1 and PBMC was done as described in Materials and methods. Controls include NL4-3 and the parental isolate MVP8913. Viral
growth was monitored by sampling medium for CA antigen every 2 days for 2 and 3 weeks, respectively. Experiments were done in quadruplicate.
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been observed best in nondividing cells such as MDM
(Heinzinger et al., 1994; Miller et al., 1994). We therefore
infected MDM from several donors with viruses derived
from the proviral clones. The parental isolate MVP8913 and
the macrophage-tropic HIV-1 M-group R5 isolate Ba-L
were used as controls. Virus derived from the initial clone
CMO2.3 barely replicated in macrophages, although the
parental isolate MVP8913 exhibited good replication
properties, albeit reduced when compared to the highly
efficient Ba-L isolate (Fig. 6B). Restoring either the vpr
open reading frame (CMO2.4) or repairing the Nef
myristoylation defect (CMO2.31) partially rescued the
replication defect of CMO2.3 (Fig. 6B). Interestingly, both
changes had a similar effect improving replication approx-Fig. 6. Replication kinetics of viruses derived from molecular clones in PBMC
CMO2.41, as well as MVP8913 and NL4-3, and replication was monitored by de
described in Materials and methods and 1  105 cells were infected 7–9 days af
inoculated with the chimeric virus CMO2.5 as well as with the Nef/Vp
Vpr+(CMO2.41) viruses. MVP8913 and the macrophage tropic isolate Ba-L were
single donor and are representative of three independent experiments with differeimately twofold. Combined restoration of the vpr and nef
defects had an additive effect in MDM, but CMO2.41 still
replicated less efficiently than the parental isolate MVP8913
(Fig. 6B). This residual defect of CMO2.41 was similar to
that observed in PBMC (Fig. 6A) and was also overcome by
exchanging the 5V fragment for that from the highly
replicative MVP2171 strain. Accordingly, infection of
MDM with CMO2.5 showed a 10-fold increase in HIV
production compared to CMO2.3, and infection kinetics
were indistinguishable from those observed for the primary
O-type isolate MVP8913. These results indicate that the
replication defect observed in CMO2.3 was partially caused
by the defects observed in nef and vpr, but additional
changes in the gag-pol region were necessary for a complete
rescue.and MDM. (A) PBMC were infected with the chimeric virus CMO2.5,
termination of CA antigen as described above. (B) MDM were prepared as
ter seeding with a virus titer of 1  104 TCID50 in triplicates. Cells were
r(CMO2.3), Nef+/Vpr(CMO2.31), Nef/Vpr+(CMO2.4), and Nef+/
used as controls. Results shown were obtained for MDM originating from a
nt donors.
D.M. Tebit et al. / Virology 326 (2004) 329–339 335Discussion
In this report, we describe the first full-length infectious
molecular clone of HIV-1 group O as well as an initial
characterization of nef-negative and vpr-negative pheno-
types in an O-group background. Since their first description
in the 1990s (De Leys et al., 1990; Gqrtler et al., 1994;
Vanden Haesevelde et al., 1994), not many studies have
been done with group-O viruses, whose earliest cases date
back to the early 1960s (Jonassen et al., 1997). The main
reason for the low number of studies with O-group viruses is
the lack of reference tools such as infectious molecular
clones. In general, the recovery of replication competent
proviruses is difficult due to the high number of defective
genomes produced during HIV replication (Li et al., 1991),
and this was underscored by the high number of defective
molecular clones (22 of 25) obtained in this study.
Furthermore, many infectious clones exhibit impaired
replication properties in primary cells, which is mostly
due to defects in nonessential accessory genes. In our study,
defects were observed in vpr and nef and repair of these
defects partly restored replication properties in PBMC and
MDM.
Although group O viruses share a similar genomic
arrangement with group M viruses, sequence homology
between these two groups is only 65% at the nucleic acid
level (Gqrtler et al., 1994). Classification of group O viruses
has been attempted based on partial genome sequences of
env, gag, and pol (Janssens et al., 1999; Mas et al., 1999;
Roques et al., 2002; Yamaguchi et al., 2002). Results from
these studies suggested that group O viruses exhibit high
diversity but do not show subtypes like group M viruses.
However, very recent analysis of 15 near full-length
genomes of HIV-1 group O isolates suggests that group O
viruses share similar intra- and inter-subtype genetic
distances like HIV-1 group M, indicating that these viruses
may indeed be classified into distinct subtypes (Yamaguchi
et al., 2003). The present study provides a new full-length
sequence and the first infectious molecular clone from an
HIV-1-O strain. More full-length sequences are required,
however, to reveal detailed and reliable phylogenetic
relationships.
Apart from the major structural genes gag, pol, and env,
HIV-1 encodes several accessory genes, tat, rev, vif, nef,
vpr, and vpu of which only tat and rev are essential for
replication. Defective accessory genes were observed in
about 50% of infectious molecular clones of HIV-1, mostly
in vpr and vpu. In this study, we observed functional defects
in vpr and nef as well as a truncation in the second coding
exon of tat. A similar truncation in tat was recently
observed in the HIV-1-O isolate 99SE-MP1299 from
Senegal (Kane et al., 2001). Previous studies also observed
premature stop codons in the second exon of tat among
HIV-1 group M subtype D strains (Gao et al., 1998). These
truncations are not likely to affect known Tat functions
because all functional domains reside upstream of thisregion. The observed defect in the vpr gene, in contrast, is
expected to completely disrupt Vpr function. This mutation
was already present as a variant in the primary isolate,
consistent with previous observations that vpr-negative
variants of HIV-1 are selected upon passage in tissue culture
(Gao et al., 1998). The change in the Nef myristoylation
signal, on the other hand, was neither detected in the
primary isolate nor in any of the known O-type sequences,
indicating that it had been caused by a PCR-induced
mutation.
Nef is a 27 kDa myristoylated membrane associated
protein that is nonessential for viral replication in tissue
culture, but is an important pathogenesis factor in vivo. One
of the consistently observed functions of Nef in virus-
infected cells in tissue culture is a nef-dependent enhance-
ment of viral replication, which is best seen in PBMC that
have not been stimulated before infection (Miller et al.,
1994; Spina et al., 1994; Welker et al., 1998). A less
pronounced effect is also observed upon infection of
prestimulated PBMC. Furthermore, nef defects have been
shown to cause attenuation of HIV-1 replication upon
infection of nondividing MDM (Miller et al., 1994). N-
terminal myristoylation of Nef is essential for membrane
attachment and for virtually all known Nef functions.
Accordingly, mutation of the myristoyl acceptor Gly2 in
the nef gene of CMO2.3 led to a loss of membrane
attachment, which could be overcome when the signal was
restored. Loss of Nef myristoylation caused a twofold
reduction of replication in stimulated PBMC and in MDM.
This result indicates that Nef of HIV-1 group O augments
the in vitro replication of the virus in PBMC and MDM, two
natural primary target cells of HIV. The effect on viral
replication appeared to be less pronounced than for M-group
viruses, where a 10- to 100-fold enhancement in PBMC and
a 5-fold enhancement in MDM has been reported (Miller et
al., 1994; Spina et al., 1994).
Vpr is another nonessential accessory protein of HIV that
is incorporated into the virion and is functionally important
for infection of nondividing cells like MDM (Heinzinger et
al., 1994). Consistent with previous reports that vpr-
mutations did not affect replication of HIV-1 group M
viruses in PBMC and T-cell lines (Connor et al., 1995; He et
al., 1995), we observed no difference in replication proper-
ties between the vpr-negative virus CMO2.3 and the vpr-
positive virus CMO2.4 in either PBMC or the PM-1 T-cell
line. A twofold increase in replication was observed in
MDM infected with CMO2.4, and this enhancing effect was
additive with that observed for nef. These results confirmed
the role of Vpr in infection of nondividing cells and
indicated that O-group Vpr performs a similar function as
group M Vpr. The observation that viruses with a stop
codon in vpr constituted the dominant population in the
primary isolate argues for a selective advantage of the vpr
virus in T-cell lines.
Most previous studies of group O viruses have been
limited to the analysis of subgenomic regions containing
D.M. Tebit et al. / Virology 326 (2004) 329–339336either structural (gag, C2V3 region of env) or accessory
genes from primary isolates (Bibollet-Ruche et al., 1998;
Brennan et al., 1997; Hackett et al., 1997; Loussert-Ajaka et
al., 1995). A detailed analysis of functional differences
between O-group viruses and other HIV strains requires that
functional analyses are performed in the context of an
infectious molecular clone. Inserting genes from O-group
viruses into M-group-derived infectious clones, however,
may not always reflect their true functional properties. The
construction of the O-group infectious molecular clone
pCMO2.5, which replicates with identical properties as a
primary O-group isolate in T-cell lines, PBMC, and MDM,
may thus serve as a reference tool for further functional
characterization of this interesting subgroup of immunode-
ficiency viruses, which are spreading slowly but continu-
ously in the global HIV-1 pandemic. Functional differences
between HIV-1 group O and M viruses include their
incorporation of and differential dependence on the cellular
protein CypA, dominant usage of CCR5 coreceptor, and the
resistance of group O viruses to some antiretroviral drugs.
Studies to address these differences will now be done by
swapping domains of interest and constructing specific
mutations in pCMO2.5.Materials and methods
Cell culture and virus propagation
293T and GHOST (Cecilia et al., 1998) cells were
propagated in Dulbecco’s modified eagle medium (DMEM)
supplemented with 10% fetal calf serum, 2 mM glutamine,
and antibiotics. PBMC were isolated from buffy coats
obtained from HIV-negative blood donors using the Ficoll-
hypaque method (Amersham Pharmacia Biotech, Uppsala,
Sweden). Immediately after isolation, PBMC were stimu-
lated with 0.5 Ag/ml phytohemagglutinin (PHA), 20 U/ml of
interleukin 2 (IL-2) was added 48 h later (Hollinger et al.,
1992). PBMC were maintained in RPMI 1640 supple-
mented as above. MDM were isolated by CD14+ selection
from purified PBMC using magnetic cell sorting (MACS)
microbeads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). Purity was 97% or higher. MDM cultures were
grown in flat bottom 96-well plates and maintained in
DMEM supplemented as above with an additional 10%
human AB serum (Sigma). Medium was changed after 5–7
days and cells were infected 7–9 days post-seeding.
The primary isolate MVP8913 was obtained from a 21-
year-old asymptomatic HIV-1-positive female Cameroonian
in 1995 and had been described previously with respect to
its coreceptor usage (Dittmar et al., 1999). Briefly, isolated
PBMC from this patient had been cocultivated with HIV-
negative PHA and IL-2-stimulated donor PBMC, and virus
stock was stored in liquid nitrogen. For this study, the isolate
was briefly passaged on PM-1 cells. Virus replication was
analyzed by a HIV capsid (CA) protein-specific antigencapture ELISA and the cell-free supernatant as well as the
cell pellet were stored at 80 8C for further analysis.
DNA isolation, long-range PCR, and construction of
full-length proviral clones
Template DNA for PCR was prepared from infected PM-
1 cells using DNAzol (GIBCO, NY, USA). Due to the
redundancy of the long-terminal repeats (LTR), the full-
length provirus was amplified in two fragments (Fig. 1A).
For the 5V fragment (5.7 kb), the primers base1Ant70 (5V-
TTCTCGAGTCGACTGGAAGGGTTAATTT-ACTCCC-
3V) hybridizing at the beginning of the 5VLTR and MLUrev2
(5V-TTGTCCCAACGCGTGTAGCCAAGGCCTAGGG3V)
at position 5714-5745 of the ANT70 genome within the vpr
gene were used. The 3V fragment (4.2 kb) extended from the
vpr gene to the end of the 3V LTR and was amplified using
the primer pair MLU for (5V-TGGCTACACGCGTTGGGA-
CAATAC-3V) and Ant70 last (5V-TTCCGCGGCCGCTGCT-
AGAGATTTTCTGCTTCAGTC-3V) hybridizing, respecQ
tively, at positions 5724–5747 and at the end of the 3V
LTR of ANT70. The underlined nucleotides indicate the
newly introduced restriction sites SalI, MluI, and NotI.
Long-range PCR was done using the Expand Long
template kit (Roche, Mannheim, Germany). PCR products
were gel purified with the Qiagen gel purification kit
(Qiagen, Hilden, Germany) and cloned into a TA vector
(Invitrogen, Groningen, The Netherlands). Four clones
bearing the 5V fragment were selected after confirmation
by restriction digest and the SalI–EcoRI fragments were
transferred into pBluescript (Stratagene, Amsterdam, The
Netherlands). Full-length clones were obtained by cleaving
the 3V PCR fragments with MluI and NotI and inserting the
respective products into the various 5V fragment-containing
plasmids that had been opened with the same enzymes.
Repair of the myristoylation signal in nef was accom-
plished by introducing an A to G exchange in an 80
nucleotide mutagenesis primer (positions 8836–8915 of
pCMO2.3), leading to a change in the second codon of
Nef from glutamic acid to glycine. The PCR product was
subsequently cloned into the full-length plasmid. The in-
frame stop codon within vpr was repaired by introducing a
T to C mutation through an 84 nucleotide mutagenesis
primer (position 5660–5744 of pCMO2.3), and the
resulting PCR-fragment was cloned into pCMO2.3. All
newly introduced PCR products were confirmed by
sequencing.
Transfections, virus titration, and replication kinetics
293T and HeLa P4 cells were transfected with 15 Ag
DNA using the calcium phosphate method, and virus
supernatant was harvested after 72 h, filtered through a
0.45-Am filter, and frozen at 80 8C. Production of HIV-1
antigen was assessed by an bin-houseQ HIV CA capture
ELISA (Tebit et al., 2002). Virus stocks derived from
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generated by infecting PM-1 cells overnight, washing cells
twice with phosphate-buffered saline (PBS) and then
cultivating them for an additional 5 days. The 50% tissue
culture infectious dose (TCID50) was determined on PM-1
cells using serially diluted virus in quadruplicate. To
determine the replication kinetics of transfection-derived
viruses in relation to the parental isolate, 5  105 PM-1 cells
and 1.5  106 PBMC were challenged with 500 TCID50 and
1500 TCID50 virus supernatant, respectively, in quadrupli-
cate in a 48-well plate and incubated overnight at 37 8C. The
next day, cells were washed twice with PBS and resus-
pended in fresh medium. Cultures were maintained for 2
and 3 weeks, respectively, and samples for CA ELISA were
collected every 2–5 days. On days 4, 8, 12, and 16, cultures
were maintained by replacing 500 Al of culture supernatant
with fresh medium. MDM seeded at 1  105 cells per well
were infected with 1  104 TCID50 in triplicates in 96-well
plates and incubated overnight at 37 8C. The next day, cells
were washed twice with PBS. Cultures were maintained for
3 weeks and 100 Al culture supernatant was sampled for
ELISA testing every 3 days and replaced with 125 Al fresh
medium.
Biological phenotypes (SI or NSI) of the viruses were
determined on MT-2 cells as described (Karlsson et al.,
1994). Infectivity was monitored by observing syncytia
formation. Chemokine coreceptor usage was determined by
infecting GHOST cells stably expressing either CCR5 or
CXCR4 in conjunction with CD4 using cell-free virus
supernatant as described previously (Tebit et al., 2002).
Immunostaining and fluorescence microscopy
PM-1 cells infected with different viruses were attached
to poly-l-lysin-coated glass coverslips for 5 min at room
temperature, fixed with 3.7% paraformaldehyde for 5 min
and permeabilized with 0.1% TritonX-100 in PBS for 1 min.
Coverslips were rinsed with PBS, blocked with 1% BSA for
30 min, and incubated for 1 h with rabbit anti-CA or mouse
anti-Nef #158 (Fackler et al., 1997). Antigen was detected
using goat anti-rabbit and anti-mouse sera (1:2000) con-
jugated with Alexa 488 and Alexa 568 (Molecular Probes,
Leiden, The Netherlands) fluorochromes, respectively.
Samples were mounted with Histogel (Linaris, Beltingen,
Germany) and images were captured with an Olympus IX-
70 fluorescence microscope and processed with Adobe
Photoshop.
Purification of virus particles and analysis of viral proteins
Culture medium from infected PM-1 cells was filtered
through a 0.45-Am pore-size filter and subsequently centri-
fuged through 20% (w/w) sucrose in PBS at 130000  g for
90 min at 4 8C. Virus pellets were resuspended in loading
buffer, subjected to sodium dodecyl sulfate (SDS)-polyacry-
lamide gel electrophoresis (PAGE), and proteins transferredto a nitrocellulose membrane (Schleicher and Schuell) by
electroblotting. Membranes were reacted either with a
mixture of polyclonal antisera against HIV-1 matrix (MA),
CA, reverse transcriptase (RT), and integrase (IN) or with
pooled patient sera from three HIV-1 O-infected patients.
Bound antibodies were detected with peroxidase-conjugated
antibodies against rabbit or human IgG (Jackson Immuno-
chemicals). Immunocomplexes were visualized using
enhanced chemiluminescence (ECL, Amersham) according
to the manufacturer’s instructions.
Sequencing and phylogenetic analysis
Sequencing was performed using the dye terminator
cycle sequencing kit on a CEQ 2000 sequencer (Beckman
Coulter, CA, USA). Contigs were assembled using the
Contig Assembler of the Vector NTI suite (Informax,
Oxford, UK). Alignment of sequences was done with the
CLUSTAL X Alignment program. Aligned sequences were
used to generate phylogenetic trees by the neighbor-joining
method of the CLUSTAL X program. Statistical robustness
of the trees and reliability of the branching pattern was
confirmed by bootstrapping (100 replicates). To determine
the similarity of this sequence to other HIV-1-O isolates and
screen for possible recombination events, the SIMPLOT
version 2.5 was used to perform similarity and bootscanning
analyses, respectively (Lole et al., 1999).
Sequence data
The full-length sequences of CMO2.3 and CMO2.5 have
been submitted to Genbank under the accession numbers
AY618998 and AY623602, respectively.Acknowledgments
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